Alzex Neuropharma Inc. (TRRI)
OTCMKTS · Delayed Price · Currency is USD
0.0002
-0.0001 (-33.33%)
At close: Dec 30, 2025

Alzex Neuropharma Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2011FY 2010FY 2009FY 2008FY 20072006
Period Ending
Dec '25 Dec '11 Dec '10 Dec '09 Dec '08 Dec '07 2006
00106-
Upgrade
Market Cap Growth
-99.95%-63.78%174.42%-91.75%--
Upgrade
Enterprise Value
-1227-
Upgrade
Last Close Price
0.00240.00900.011500.0218000.18-
Upgrade
PE Ratio
0.0114.5116.10-25.46-
Upgrade
PS Ratio
0.000.100.340.050.38-
Upgrade
PB Ratio
0.000.451.070.7517.18-
Upgrade
P/FCF Ratio
-1.6217.85-16.53-
Upgrade
P/OCF Ratio
0.001.6217.85-15.87-
Upgrade
EV/Sales Ratio
-0.230.630.200.49-
Upgrade
EV/EBITDA Ratio
-118.3213.13---
Upgrade
EV/EBIT Ratio
--21.37---
Upgrade
EV/FCF Ratio
-3.8133.47-21.29-
Upgrade
Debt / Equity Ratio
0.600.600.702.134.21-39.98
Upgrade
Debt / EBITDA Ratio
67.4167.414.56---
Upgrade
Debt / FCF Ratio
2.172.1711.64-4.051.45
Upgrade
Asset Turnover
2.252.251.704.136.966.99
Upgrade
Quick Ratio
1.401.401.822.701.472.16
Upgrade
Current Ratio
1.431.431.912.721.532.28
Upgrade
Return on Equity (ROE)
2.85%2.85%8.75%-69.49%157.92%-206.92%
Upgrade
Return on Assets (ROA)
-1.64%-1.64%3.14%-7.95%-6.10%-9.76%
Upgrade
Return on Capital Employed (ROCE)
-3.30%-3.30%5.40%-13.30%-12.20%-18.00%
Upgrade
Earnings Yield
10648.84%6.89%6.21%-70.64%3.93%-
Upgrade
FCF Yield
-61.58%5.60%-50.93%6.05%-
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.